Fasting makes brain tumors more vulnerable to radiation therapy

A new study from USC researchers is the first to show that controlled fasting improves the effectiveness of radiation therapy in cancer treatments, extending life expectancy in mice with aggressive brain tumors.

Prior work by USC professor of gerontology and biological sciences Valter Longo, corresponding author on the study and director of the Longevity Institute at the USC Davis School of , has shown that short-term fasting protects healthy cells while leaving vulnerable to the toxic effects of chemotherapy.

The latest study, appearing online once the embargo lifts in PLOS One, is the first to show that periods of fasting appear to have the same augmenting effect on in treating gliomas, the most commonly diagnosed brain tumor. Gliomas have a median survival of less than two years.

"With our initial research on chemotherapy, we looked at how to protect patients against toxicity. With this research on radiation, we're asking, what are the conditions that make cancer most susceptible to treatment? How can we replicate the conditions that are least hospitable to cancer?" Longo said.

Longo and his co-investigators studied the combination of fasting with radiation therapy and with the chemotherapy drug Temozolomide, currently the standard treatment for the treatment of brain tumors in adults after an attempt at surgical removal.

They found that controlled short-term fasting in mice, no more than 48 hours each cycle, improved the effectiveness of radiation and chemotherapy in treating gliomas. Despite the extremely aggressive growth of the type of brain tumor studied, more than twice as many mice who fasted and received radiation therapy survived to the end of the trial period than survived with radiation alone or fasting alone.

"The results demonstrate the beneficial role of fasting in gliomas and their treatment with standard and radiotherapy," the researchers write, who say the results indicate the benefits of short-term, controlled fasting for humans receiving treatment for .

Longo cautions that patients should consult with their oncologist before undertaking any fasting: "You want to balance the risks. You have to do it right. But if the conditions are such that you've run out of options, short-term fasting may represent an important possibility for patients."

Related Stories

Recommended for you

New breast cancer imaging method promising

1 hour ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

1 hour ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

3 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

7 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments